Welcome to our dedicated page for Atossa Therapeutics news (Ticker: ATOS), a resource for investors and traders seeking the latest updates and insights on Atossa Therapeutics stock.
Atossa Therapeutics Inc (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company pioneering novel therapies for breast cancer and breast health conditions. This page provides investors and healthcare stakeholders with comprehensive access to official press releases, clinical trial developments, and regulatory updates directly from the company.
Track progress on key initiatives including (Z)-endoxifen clinical trials, innovative drug delivery systems like intraductal microcatheter technology, and strategic partnerships. Our curated news collection ensures timely updates on FDA communications, research milestones, and intellectual property developments relevant to oncology therapeutics.
Discover updates across three primary categories: clinical research advancements in estrogen receptor-targeted treatments, regulatory filings for breast cancer therapies, and scientific collaborations enhancing drug delivery platforms. Each update is sourced from verified company communications to maintain accuracy and compliance.
Bookmark this page for streamlined access to Atossa's latest developments in selective estrogen receptor modulation and precision medicine. Regularly updated to serve as your primary resource for understanding the company's progress in addressing unmet needs in oncology care.
Atossa Therapeutics (Nasdaq: ATOS) announced a registered direct offering of $50 million in common stock and warrants priced at $2.88 per share. The agreement involves the sale of 17,361,100 shares and unregistered warrants for an additional 13,020,825 shares with a four-and-a-half-year expiration period. The offering, expected to close on March 24, 2021, is facilitated by Maxim Group LLC. Proceeds will support the company's clinical-stage operations focusing on oncology and infectious diseases. This move may impact shareholder equity through potential dilution.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced that the FDA issued a "Safe to Proceed" letter allowing the use of their oral Endoxifen as a treatment for a patient with recurrent ovarian cancer. The treatment is being conducted at the University of Washington Medical Center by Dr. Barbara Goff. The patient's tumor responded well to a combination of Endoxifen and alpelisib, prompting Atossa to consider further clinical studies if successful.
Endoxifen, an active metabolite of tamoxifen, has shown significant efficacy in preclinical studies.
Atossa Therapeutics (Nasdaq: ATOS) released final results from its Phase 1 trial of AT-301, a nasal spray for COVID-19, indicating the treatment was safe and well-tolerated. Conducted on 32 healthy participants, the trial noted no serious adverse events, with only one case of moderate adverse events. The company plans to begin a pre-clinical study this quarter and aims to initiate a Phase 2 study in the U.S. AT-301 may also serve as a preventive measure against COVID-19, particularly in high-risk environments. The mechanism of AT-301 targets viral entry, suggesting potential effectiveness against variants.
Atossa Therapeutics (Nasdaq: ATOS) has provided an update on its progress amid the COVID-19 pandemic. The company raised approximately $81 million in net proceeds, enabling continued development in oncology and infectious diseases. Key developments include:
- AT-301 Nasal Spray for COVID-19, with Phase 1 study data expected in Q1 2021.
- AT-H201 Inhalation Therapy showing potential in clinical tests.
- Oral Endoxifen demonstrating significant tumor cell proliferation reduction.
Atossa's commitment to innovative therapies remains strong.
Atossa Therapeutics (Nasdaq: ATOS) reported promising results from a 26-month Expanded Access study involving its oral Endoxifen for a breast cancer patient. The patient has not experienced a recurrence of cancer, nor any adverse treatment-related effects, and has tolerated the drug well compared to tamoxifen. FDA authorization allowed the use of Endoxifen before and after surgery, marking a significant step in its development. The CEO noted the patient's experience as a model for future drug development efforts in addressing unmet medical needs.
Atossa Therapeutics (Nasdaq: ATOS) announced the receipt of $21 million from the exercise of outstanding warrants, contributing to a total of approximately $60 million raised since December 2020. The funds will accelerate the development of therapies for COVID-19 and breast cancer. CFO Kyle Guse emphasized the significance of these cash resources, stating they enable faster advancement of their programs in 2021. This financing marks a crucial step for Atossa as it seeks to address significant unmet medical needs in the biopharmaceutical sector.
On January 29, 2021, Dr. Steven Quay, CEO of Atossa Therapeutics, published a 193-page paper concluding that SARS-CoV-2 is 99.8% likely to be laboratory-derived rather than a natural zoonosis. The analysis scrutinized 26 independent facts, shifting initial beliefs from a 98.2% zoonotic origin to a strong lab-related conclusion. Dr. Quay raised concerns about potential conflicts of interest hindering true investigation into the virus's origin, especially citing genetic sequences linked to adenovirus vaccines in early Wuhan samples. The full paper is available on Zenodo for public access.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) will present a webinar titled “The Important Role of COVID Therapeutics in a Post Vaccine World” on February 2, 2021. CEO Dr. Steven Quay and CFO Kyle Guse will discuss the company’s focus on developing innovative medicines, particularly addressing COVID-19 and breast cancer. This complimentary event is hosted by Tribe Public and begins at 8am Pacific/11am Eastern. Participants can submit questions prior to the event or during the live session. Registration is available through Tribe Public's website.
Atossa Therapeutics (Nasdaq:ATOS) announced that Dr. Steven C. Quay will participate in the 2021 Precision Medicine World Conference, focusing on the development of new SARS-CoV-2 therapeutics. The event occurs virtually from January 25-27, 2021, with Dr. Quay's panel scheduled for January 26 at 11:30 AM PST. The conference highlights advancements in precision medicine and features notable speakers, including Dr. Anthony S. Fauci, the Director of the U.S. National Institute of Allergy and Infectious Diseases.
Dr. Steven Quay, M.D., PhD, recently shared insights into COVID-19's origins and spread, linking early cases to the People's Liberation Army Hospital in Wuhan, China, and the city's Metro Line 2. He noted a genetic cluster among four patients with a similar virus version, suggesting rapid global transmission via the subway system. Quay emphasized the importance of understanding these origins for improving treatments. His research continues to explore whether COVID-19's emergence was due to a market or laboratory incident, with potential revelations expected soon.
